

Construction of cuproptosis-associated prognostic signature in colon adenocarcinoma based on bioinformatics and RT-qPCR analysis

GUANG YANG¹, HAIPING WANG² and BINLIAN SUN²

¹Medical Experimental Center; ²Institute of Biomedical Sciences, School of Medicine, Jiangnan University, Wuhan, Hubei 430056, P.R. China

Received September 21, 2022; Accepted December 30, 2022

DOI: 10.3892/ol.2023.13677

Abstract. Colon adenocarcinoma (COAD) is the most common pathological subtype of colon cancer with a high degree of malignancy. Cuproptosis is a newly discovered copper-dependent cell death pattern distinguished from all the other known programmed cell death. Hence, it can be used as a potential therapeutic target for cancer. The present study aimed to clarify the relationship between cuproptosis and prognosis of COAD. The variations of 12 cuproptosis-associated genes based on 623 patients with COAD were comprehensively identified. It was found that 8 out of 12 were differentially expressed in tumors and normal tissues and *CDKN2A* showed a higher prognostic value. Therefore, two molecular subtypes were explored and the subtype A, with higher expression of cuproptosis-associated genes, showed more enrichment of immune pathways and survival advantage over those with lower cuproptosis-associated genes expression. The risk score and a nomogram predicting pattern were constructed to quantify a single patient and the risk score could serve as an independent prognostic factor by multivariate Cox regression analysis ($P < 0.001$, HR: 1.350, 95% CI: 1.189-1.534). The expression levels of key prognostic genes (*PMM2*, *ACOX1*, *KDM3A*, *HSPB1*, *PPARGC1A*, *UPK3B* and *EPHB2*) was analyzed by HCT-116 colon cancer cells and HT-29 colorectal cancer cells using reverse transcription-quantitative PCR. The

high-risk group, characterized by higher immune infiltration, increased microsatellite instability-high, high tumor mutation burden and high expression level of immune checkpoints, indicated higher drug sensitivity. In conclusion, our analysis confirms the potential role of cuproptosis-associated genes in the prognosis of COAD and it will provide new ideas for immunotherapy.

Introduction

Colon adenocarcinoma (COAD) is the third leading cause of cancer-related mortality worldwide and the fatality rate is as high as 50.2%, according to statistics for 2020 (1). COAD accounts for 80-90% of colon cancer on the basis of pathological classification. At present, the 5-year survival rate of patients with COAD without distant metastasis has an improved prognosis, but the survival rate of patients with distant metastases is $<30\%$ (2). Target therapies and immune checkpoint blockade therapies have shown desirable results in both early-stage and advanced-stage colon cancer, but resistance is a major unsolved problem (3,4). Therefore, a comprehensive understanding of the genetic variation and Tumor microenvironment (TME) of colon cancer is the best choice for treatment and prognostic assessment.

In the 1960s, the era of cancer treatment using copper was beginning (5). A previous study confirmed higher levels of copper in the serum and tumor tissue compared with that in healthy subjects (6). Copper participates in the proliferation, angiogenesis and metastasis of tumors (7). Therefore, abnormal copper levels may be a new target for cancer therapy (8). Unbalanced copper homeostasis may cause irreversible damage to cells. The cell death mechanism caused by copper is distinct from all the other known programmed cell death mechanisms, such as apoptosis, pyroptosis, ferroptosis and necroptosis, and this non-specific mechanism is termed 'cuproptosis' (9). Cuproptosis, as a new form of programmed cell death, sheds light on tumor treatments. According to a recent study, cuproptosis is mediated by an ancient mechanism: Mitochondrial respiration. Mitochondria are essential regulators of cell proliferation and the dysregulation of mitochondrial function are closely associated with colon cancer (10). A close correlation between blood copper levels

Correspondence to: Dr Guang Yang, Medical Experimental Center, School of Medicine, Jiangnan University, 8 Triangle Lake Road, Wuhan Economic and Technological Development Zone, Wuhan, Hubei 430056, P.R. China
E-mail: yangguang@jhun.edu.cn

Dr Binlian Sun, Institute of Biomedical Sciences, School of Medicine, Jiangnan University, 8 Triangle Lake Road, Wuhan Economic and Technological Development Zone, Wuhan, Hubei 430056, P.R. China
E-mail: binlian17@jhun.edu.cn

Key words: cuproptosis, colon adenocarcinoma, prognosis, tumor microenvironment, immunotherapy

and colorectal cancer has been discovered (11). However, the relationship between COAD and cuproptosis-associated genes remains to be elucidated. The following genes, *FDX1*, *LIPT1*, *LIAS*, *DLD*, *DLAT*, *PDHA1* and *PDHB* can rescue cells from cuproptosis, while the three other genes (*MTF1*, *GLS* and *CDKN2A*) are the sensitizers of cuproptosis through whole genome CRISPR-Cas9 knockout screening (9). Copper ionophores, including the importer *SLC31A1* (12) and copper chelators, including the exporters *ATP7B* (13-15) were used to maintain the copper homeostasis. The overexpression of *SLC31A1* and deletion of *ATP7B* could increase sensitivity to cuproptosis. These 12 genes have been confirmed to be closely associated with cuproptosis (9). The correlation of cuproptosis with prognosis of COAD remains to be elucidated. Therefore, the role of cuproptosis in tumorigenesis and the relationship between cuproptosis-associated genes and COAD are waiting for exploration.

The present study explored the potential relationship between 12 cuproptosis-associated genes and COAD. Patients with COAD were divided into two cuproptosis-related molecular subtypes according to the expression levels of 12 cuproptosis-associated genes in each sample. The patients were then classified into three gene subtypes according to differentially expressed genes (DEGs) of prognostic value based on the two cuproptosis-related subtypes. Finally, a risk score and a nomogram predicting pattern were established to predict survival probability and immune characteristics of COAD, which may predict patient prognosis and immunotherapeutic sensitivity.

Materials and methods

COAD data integration. The RNA transcriptome dataset [Fragments Per Kilobase Million (FPKM)], tumor somatic mutation data and clinical data of COAD including survival time, survival status, age, sex, stage and tumor node metastasis TMN classification, which were downloaded from the Cancer Genome Atlas (TCGA; <https://portal.gdc.cancer.gov/>) database on April 22, 2022. GSE17536 was obtained from the Gene Expression Omnibus (GEO; <https://www.ncbi.nlm.nih.gov/geo/>). All mRNA expression data were collected from human tumor or para-carcinoma tissues. FPKM format was transformed into the Transcripts Per Kilobase Million (TPM) form (16,17). The batch effect of the merged datasets and other unrelated variables were removed by the package SVA of R software 4.1.1 (<https://www.r-project.org/>) (18). Patients without clinical information were excluded, a total of 623 patients were included in the subsequent analyses.

Identification of subtypes and biological function enrichment. The consensus unsupervised clustering analysis was used to stratify patients into distinct molecular subtypes according to the expression levels of 12 cuproptosis-associated genes in each patient. The differences in prognosis and survival rate of subtypes were assessed using the univariate Cox regression and the Kaplan-Meier survival analysis generated by the 'survival' and 'survminer' R packages (19). Gene set variation analysis (GSVA) was applied to ascertain the different enrichment of molecular subtypes in biological processes with the Kyoto Encyclopedia of Genes

and Genomes (KEGG) and Hallmark gene set (<http://www.gsea-msigdb.org/gsea/downloads/c2.cp.kegg.v7.5.1.symbols.gmt> and [h.all.v7.5.1.symbols.gmt](http://www.gsea-msigdb.org/gsea/downloads/h.all.v7.5.1.symbols.gmt) were downloaded on June 25, 2022.).

Construction of the risk score. The risk score associated with cuproptosis prognosis was calculated to quantify the individual colon tumors. First, the differentially expressed genes (DEGs) between the cuproptosis subtypes were identified and the prognostic DEGs were screened out by the univariate Cox regression analysis with $P < 0.001$, to classify the patients into three subtypes (cuproptosis gene subtype A, B and C) using a consensus unsupervised clustering method. Second, based on the prognostic DEGs, the least absolute shrinkage and selection operator (LASSO) Cox regression algorithm was applied to minimize the risk of over-fitting by the 'glmnet' R package (19). Last, the key genes and their correlative coefficients were obtained using multivariate Cox analysis to establish risk score. The risk score of each patient was calculated as follows:

$$\text{Risk score} = \sum_{i=1}^n (\text{Exp}_i \times \text{Coef}_i)$$

Exp_i and Coef_i represented each gene's expression and correlative coefficient, respectively. The patients were divided into the low-risk group (<median value) or the high-risk group (≥median value) (19). The median is a measure of the central tendency of the data and represents the general level of the data, which means that a lot of the data in a dataset are not affected by the data that is too large or too small. The 'survival' R package was used to determine the survival rate of two risk groups. Finally, in order to verify the reliability of the risk score, all patients with COAD were randomly categorized into the internal group (training group, n=312) and the external validation groups (testing group, n=311) with the R package 'caret' (19).

To assess whether the risk score was independent of other clinicopathological features, forest maps for univariate and multivariate independent prognostic analyses were performed. A time-dependent receiver operating characteristic (ROC) curve was used to evaluate the reliability of prognosis for 1-, 3-, 5-years. In addition, the present study investigated whether the risk score maintained its superior performance to the traditional clinicopathological features (age, sex, stage, T, M, N) by the ROC curve.

Reverse transcription-quantitative (RT-q) PCR. Total RNA was extracted from HCT-116 colon cancer cell lines and HT-29 colorectal cancer cell lines (1x10⁵/ml; American Type Culture Collection) using TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc.) and TB Green Premix Ex TaqTM II (Takara Bio, Inc.). Complementary DNA (cDNA) was synthesized using the total RNA and a PrimeScript RT reagent kit (Takara Bio, Inc.). SYBR Green assays were used to perform the RT-qPCR on CFX 96 Thermocycler (Bio-Rad Laboratories, Inc.). RNA extraction, cDNA synthesis, and qPCR were performed according to the manufacturer's protocols. Amplification conditions were 5 min at 95°C and then 40 cycles each consisting of 10 sec at 95°C, 1 min at 60°C and 10 sec at 72°C. The data were calculated through the 2^{-ΔΔC_q} (19), normalizing with GAPDH. The primer sequences used for RT-qPCR in

this study are listed in Table SI. Experiments were repeated three times.

Analysis of immune function, checkpoints, tumor mutation burden (TMB), microsatellite instability (MSI) and drug susceptibility between two risk groups. TIMER, CIBERSORT, CIBERSORT-ABS, quanTiseq, MCP-counter, xCell and EPIC algorithms (20) were used to assess the expression level of immune cells by correlation analysis of risk score. The present study also validated differential expression of immune cell subpopulations-related function, immune checkpoints and MSI between low- and high-risk groups. Next, the datasets of 448 COAD-related mutations from the TCGA database were downloaded to compare the score of TMB by Spearman correlation analysis. To explore the difference of drug susceptibility between the two risk groups, the 'pRRophetic' algorithm and 'ggpubr' packages (19) were used to calculate the semi-inhibitory concentration (IC_{50}) values of commonly used immunotherapeutic drugs in cancer treatment.

Construction of a nomogram scoring pattern. Nomogram scoring pattern was constructed by the 'Regplot' package based on the results of independent prognostic analyses according to different clinical characteristics and risk score (21). In the nomogram scoring pattern, each variable was matched with a score. The scores of all variables in each patient were added to get the total scores (22), which would indicate the survival probability of each patient <1-, 3-, 5-years, respectively.

Statistical analyses. All statistical analyses were performed by R version 4.1.1 and $P < 0.05$ was considered to indicate a statistically significant difference. Significant differences of model genes between the normal group and HCT-116 or HT-29 cells in the RT-qPCR analysis were measured by two ways of analysis of variance with Bonferroni's post-test.

Results

Variation of cuproptosis-associated genes in COAD. The analysis flow chart is Fig. S1. First, copy number variation (CNV) of 12 cuproptosis-associated genes were explored and it was found that *PDHB* had the highest CNV deletion followed by *FDX1*, *CDKN2A*, *DLAT*, *LIAS*, *DLD*, whereas *ATP7B*, *MTF1*, *GLS* and *LIPT1* had CNV amplification (Fig. 1A). The circle graph shows the location of CNV alteration on respective chromosomes (Fig. 1B). Furthermore, the expression level of cuproptosis-associated genes between normal tissues and COAD was compared. It was discovered that *PDHA1*, *ATP7B*, *CDKN2A*, *GLS* and *LIPT1* were significantly increased in tumor tissues, but *MTF1*, *DLD* and *FDX1* were increased in normal tissues. The expression levels of most genes were positively correlated with the change in CNV. Compared with normal tissues, CNV loss such as *FDX1* and *DLD* was expressed at lower levels in tumors, while CNV gain such as *ATP7B*, *GLS* and *LIPT1* were significantly increased in tumors, suggesting that CNV regulates mRNA expression of genes (Fig. 1C). However, CNV deletion of *CDKN2A* showed higher expression in tumors, while CNV amplification of *MTF1* downregulated mRNA expression in tumors. It might be that CNV is not the only factor that regulates mRNA expression (23). Other factors,

such as transcription factors or DNA methylation, can also regulate mRNA expression (24,25). It was observed that 11 out of 12 genes were positively regulated by polygenic correlation analysis, but *CDKN2A* was an exception (Fig. 1D). Last, the prognosis of 12 cuproptosis-associated genes was performed and *CDKN2A* was identified as the best independent predictive factor ($P = 0.034$; HR: 1.20985; 95% CI: 1.06503-1.37437). The results indicated that the genetic variation and expression of 12 cuproptosis-associated genes are different between normal tissues and COAD, indicating that they have a potential role in tumorigenesis.

Identification of cuproptosis subtypes and enrichment analysis of biological function. The present study categorized 623 patients into two subtypes, including 302 cases in subtype A and 321 cases in subtype B, based on the optimal selection $k = 2$. The cumulative distribution function (CDF) curve increased gradually and smoothly (Fig. 2A). These were termed cluster A and B, respectively. The survival analysis showed cluster A had an improved survival rate than cluster B within seven years (Fig. 2B). The differences between the two subtypes were revealed by principal component analysis (PCA) analysis (Fig. 2C). Furthermore, a heat map of the clinical characteristics of two clusters showed that most cuproptosis-associated genes were highly expressed in cluster A, while the minority was expressed in cluster B (Fig. 2D). But *CDKN2A* was highly expressed in cluster B. It was hypothesized that *CDKN2A* was associated with tumorigenesis and had an impact on survival. *CDKN2A* can be regarded as a promising biomarker of colon cancer (26). *CDKN2A*, as an important marker of epithelial-mesenchymal transition, tends to be upregulated in colon cancer (27). Cluster B had more mortality and advanced stage (stage III-IV) compared with cluster A. Finally, gene set variation analysis (GSVA) analysis in KEGG showed that cancer or immune-related pathways, molecular processes, including endometrial cancer, cell cycle, ubiquitin-mediated proteolysis and TCA cycle pathway were enriched in cluster A (Fig. 2E). Additionally, the GSVA in Hallmark found the diverse pathways were highly enriched in cluster A, such as MYC targets, G2M checkpoint, E2F targets, unfolded protein response and PI3K/AKT/mTOR signaling. According to the above analyses, it was hypothesized that cuproptosis-associated genes might regulate immune-related and cell death-related molecular processes and pathways to inhibit the progression of tumors (28).

Identification of gene subtypes and construction of the risk score. The two subtypes were compared to find 5,366 DEGs from the intersection. The prognostic values of 29 genes were subsequently screened by univariate Cox regression analysis. Corresponding to cuproptosis-related subtypes, the consensus clustering algorithm was also used to stratify patients into three genomic subtypes based on 29 prognostic genes termed gene subtypes A, B and C. The survival curves showed that gene cluster A had the best survival advantages over the other two clusters (Fig. 3A). In addition, there were significant differences in the expression level of cuproptosis-associated genes among the three gene subtypes and most of them were highly expressed in subtype A (Fig. 3B). As expected, *CDKN2A* was highly expressed in cluster C with the poorest survival rate. To




Figure 1. Variation of cuproptosis-associated genes in COAD. (A) Histogram plotting the copy number variation frequency. The abscissa was cuproptosis-associated genes and the ordinate was the CNV frequency. Red represents increasing in copy number and blue represents loss of copy number. (B) Locations of CNV alterations on 23 chromosomes. Red means the sample with increasing copy number is larger than the sample with lost copy number. Blue means the sample with missing gene copy number is larger than the sample with increasing copy number. Black indicates the same number of copies. (C) Expression distributions of 12 cuproptosis-associated genes between normal and COAD tissues. Red represents the tumor samples, blue represents the normal sample. ** $P < 0.01$ and *** $P < 0.001$. (D) The polygenic correlation analysis of 12 cuproptosis-associated genes based on TCGA-COAD and GSE17536. COAD, colon adenocarcinoma; CNV, copy number variation; TCGA, the Cancer Genome Atlas.

further understand the characteristics of cuproptosis in each patient, the risk score was established, the key 7 model genes and their correlative coefficients were obtained by LASSO and multivariate Cox regression analysis (Table SII), including three high-risk genes (*KDM3A*, *HSPB1* and *UPK3B*) and four low-risk genes (*PMM2*, *ACOX1*, *PPARGC1A* and *EPHB2*). The risk score of each patient was constructed as follows:

$$\text{Risk score} = (-0.34559 \times \text{expression}_{\text{PMM2}}) + (-0.44662 \times \text{expression}_{\text{ACOX1}}) + (0.79297 \times \text{expression}_{\text{KDM3A}}) + (0.14968 \times \text{expression}_{\text{HSPB1}}) + (-0.20650 \times \text{expression}_{\text{PPARGC1A}}) + (0.19863 \times \text{expression}_{\text{UPK3B}}) + (-0.14950 \times \text{expression}_{\text{EPHB2}}).$$

The patients with risk score lower than the median value of 0.9555921 were categorized into the low-risk group ($n=312$), while those with risk score higher than the median value were placed in the high-risk group ($n=311$). The discernible separation between high- and low-risk groups was conducted by PCA analysis (Fig. 3C). As the risk score increased, patient mortality increased (Fig. 3D). It was discovered that the risk score showed different distribution in cuproptosis clusters and

gene clusters. The risk score of gene cluster C was the highest, while cuproptosis-related cluster B was markedly correlated with a higher risk score (Fig. 3E and F). The Sankey diagram showed the changes in attributions of individual patients and the majority of patients from the low-risk group survived (Fig. 3G). The above results indicated the risk score was negatively correlated with the patient's survival, while survival rates decreased with increased risk scores.

To validate the prognostic reliability of risk score, all patients were randomly stratified into the training group ($n=312$) and the testing group ($n=311$). The patients were also classified into low- or high-risk groups according to the above risk score formula and the median value. The three high-risk genes (*KDM3A*, *HSPB1* and *UPK3B*) were highly expressed in the high-risk group according to the heat map and the survival status distribution plot revealed that as the risk score increased, the mortality also increased (Fig. 4A). Survival analysis revealed a significantly improved prognosis in the low-risk group than in the high-risk group ($P < 0.001$; Fig. 4B). Furthermore, the area under the curve (AUC) values of the patients' 1-, 3-, 5-year survival rates were predicted as 0.681,




Figure 2. Cuproptosis-associated two subtypes and biological function enrichment. (A) Consensus matrix heatmap defining two clusters (k=2) and the area under CDF curve. (B) Survival analysis of two cuproptosis subtypes. (C) PCA analysis showing a difference among the two subtypes. (D) Differences expression levels of cuproptosis-associated genes in clinical features among the two distinct subtypes. (E) GSEA analysis of biological pathways in KEGG and Hallmark, respectively. In which red represent activated pathways and blue represent inhibited pathways. CDF, cumulative distribution function; PCA, principal component analysis; GSEA, gene set variation analysis; KEGG, Kyoto Encyclopedia of Genes and Genomes.

0.684 and 0.770 in the entire group, respectively. The AUC value of training and testing groups were all >0.6 (Fig. 4C). The patient survival status distribution plot, survival analysis and ROC showing the same tendencies of the two risk groups in the entire, training and testing groups. All of these indicated that the risk score had a stable performance to predict the prognosis of patients with COAD.

Analysis of independent prognosis and immune infiltration of risk score. To further confirm that the risk score was superior to the other clinical characteristics, univariate and multivariate independent prognostic analyses were performed. The risk score was confirmed as an independent prognostic factor ($P<0.001$; HR: 1.350; 95% CI: 1.189-1.534; Fig. 5A and B). ROC curves were used to determine whether the risk score

could be used as an early prediction for COAD. It was found the area under the risk score curve of 5-year AUC was the largest, implying that the sensitivity and specificity of this prognostic pattern are more feasible than the other clinical factors (Fig. 5C). The high-risk group was closely associated with higher stromal scores and immune scores by difference analysis in the TME (Fig. 5D), suggesting the higher estimate scores and the lower tumor purity in the high-risk group. Analysis of gliomas showed that tumors with lower purity had higher malignancy and worse prognosis (29). Low tumor purity was an independent predictor of poor prognosis in colon cancer with a higher TMB and stronger immunophenotype (30). As shown in Fig. 5E, the abscissa is the correlation coefficient of the risk score. If the correlation coefficient was >0 , the expression level of immune cells was positively correlated with the




Figure 3. Construction of the risk score. (A) Survival curves for overall survival of the three gene subtypes ($P < 0.001$). (B) Differences in the expression of 12 cuproptosis-associated genes among the three gene subtypes. $^*P < 0.05$, $^{**}P < 0.01$ and $^{***}P < 0.001$. (C) PCA analysis based on two risk groups. The orange and blue dots represent low-risk and high-risk groups, respectively. (D) Box chart analysis of the risk score for patients with COAD by status. (E) Differences in risk score among gene subtypes. (F) Differences in risk score among cuproptosis subtypes. (G) Sankey diagrams of different status, risk score, gene cluster and cluster. COAD, colon adenocarcinoma.

risk score; otherwise, it was negatively correlated. The expression levels of most immune cells was positively correlated with the risk score and it demonstrated that most immune cells tended to be higher enriched in the high-risk group. In addition, the association between individual immune cells and risk score was confirmed by correlation analysis. The risk score was negatively correlated with plasma B cells, resting NK cells and activated memory $CD4^+$ T cells (Fig. S2A-C; $R < 0$; $P < 0.05$). By contrast, the risk score was positively correlated with endothelial cells, M0 macrophages, M1 macrophages, M2 Macrophages, $CD8^+$ T cells and T cell regulatory cells (Tregs; Fig. S2D-I; $R \geq 0$; $P < 0.05$). As shown in Fig. 5F, VEGF/toll-like receptor/TGF β /T cell receptor/Rig I-like

receptor/NOTCH/MAPK/chemokine signaling pathways were positively correlated with the risk score, demonstrating that these immune-related pathways were enriched in the high-risk group.

To investigate the differences in clinical characteristics in high- and low-risk groups, the percent weight of age, sex, stage, T, M, N was explored in two risk groups. The results showed that patients of age > 65 , male, advanced-stage tumor stage, T and M occupied the higher proportion in the high-risk group (Fig. S3A-F).

RT-qPCR analysis. The expression levels of seven model genes in HCT-116 and HT-29 cells were investigated by




Figure 4. Construction of the risk score in the entire, training and testing groups. (A) Heatmap, ranked dot and scatter plots showing the risk score distribution and patient survival status. (B) Survival analysis of entire, training and testing groups. (C) ROC curves to predict the sensitivity and specificity of 1-, 3- and 5-year survival according to the risk score in the entire, training and testing groups, respectively. ROC, receiver operating characteristic.

RT-qPCR and the expression of *HSPB1* was the highest in tumor cells compared with normal tissue cells. As a low-risk gene, *PPARGC1* is highly expressed in normal tissues. The expression levels of *PMM2*, *ACOX1* and *UPK3B* were upregulated in HCT-116 and HT-29 cells and *KDM3A*, *EPHB2* only in HCT-116 colon cancer cells compared to the expressed levels in the normal tissue cells (Fig. 6A-G). By RT-qPCR analysis, the expression trend of most model genes between normal and tumor tissues was basically consistent with the results based on TCGA data analysis (Fig. 6H-N).

Immune function, checkpoints, TMB, MSI and drug susceptibility analysis. The immune cell subpopulations related functions between two risk groups were evaluated by ssGSEA analysis and the following T cell functions: APC co-inhibition, checkpoint, HLA, para inflammation, T cell co-inhibition and type I/II IFN response were highly enriched in the high-risk group (Fig. 7A). A previous study has elucidated the critical role of checkpoint inhibitor utilized in immunotherapies (31). Therefore, the differences in the expression levels of 23 immune checkpoints between the two risk groups was investigated and the expression levels of CD274 (PD-L1), PDCD-1 (PD-1) and CTLA 4, etc. in the high-risk group were significantly higher than those in the low-risk group (Fig. 7B). The above results demonstrated that

the high-risk group had a great deal of immune cell infiltration, the enrichment of immune-related pathways and a higher expression level of immune checkpoints. It might be more sensitive to immunotherapies.

Based on the risk score, the differences in TMB, MSI and drug sensitivity between the two risk groups was assessed. Some evidence suggests that patients with high TMB may benefit from immunotherapy (5). Fig. 7C showed that the high-risk group had a higher TMB compared with the low-risk group, indicating that an apparent positive correlation could be displayed between risk score and TMB. Spearman correlation analysis confirmed the above results ($r_s=0.15$; $P=0.0023$; Fig. 7D). According to the TMB optimal cut-off value, patients were divided into the high- and the low-mutation group. The prognosis of low-TMB was improved compared with that of high-TMB through survival analysis (Fig. 7E). MSI-H increased with the increases of risk score (Fig. 7F) and the patients with high-frequency MSI-H are more sensitive to and benefit greatly from immunotherapies (11). Finally, commonly used immunotherapeutic drugs and the copper ion carrier Elesclomol were searched to evaluate the sensitivities of patients in two risk groups. Most patients in the high-risk group had lower IC_{50} values, such as Elesclomol, Indoximod, nivolumab and Pazopanib (Fig. 7H-M), while Cytarabine was lower in the low-risk group. Together, these results confirmed




Figure 5. Independent prognosis and immune infiltration analyses. (A) Univariate Cox regression analysis identification of individual factors associated with patient survival. (B) Multivariate Cox regression analysis identify independent prognostic factors and the result indicated that the risk score could as independent prognostic factors (HR:1.350, 95% CI: 1.189–1.534). Green represents the value of hazard ratio in univariate and red represents the value of HR in multivariate analysis. (C) The feature of AUC with a risk score of 5-year was superior to traditional clinicopathological features in predicting prognosis. (D) Correlations between risk score and immune, stromal scores and tumor purity, * $P < 0.05$, ** $P < 0.01$ and *** $P < 0.001$. (E) The correlation coefficient of immune cell expression. The TIMER, CIBERSORT, CIBERSORT-ABC, quantTseq, MCP-counter, xCell, EPIC algorithms to assess the expression level of different immune cell types. (F) KEGG pathway enrichment analysis: the abscissa is the patient's KEGG pathways and the ordinate are seven model genes and risk score. Red is positive, green is negative. HR, hazard ratio; CI, confidence interval; KEGG, Kyoto Encyclopedia of Genes and Genomes; AUC, area under the curve




Figure 6. RT-qPCR analysis. (A-G) Relative expression levels of 7 model genes in HCT-116 colon cancer and HT-29 colorectal cancer cell lines and corresponding normal tissue cell line by RT-qPCR. ns, not significant, * $P < 0.05$, ** $P < 0.01$ and *** $P < 0.001$. (H-N) The distribution of seven model genes between normal and tumor tissues. RT-qPCR, reverse transcription-quantitative (RT-q) PCR.

that the patients in the high-risk group were more sensitive to immunotherapy.

Construction of a prognostic nomogram pattern. Considering the practicability of the risk score in predicting the survival status of patients with COAD, a nomogram scoring pattern combining risk score and clinicopathological characteristics was established to predict survival probability in 1-, 3- and 5-years. As shown in Fig. 8A, the score of age was 48, the score of risk score was 22 in the low-risk group and the total score was 466, predicting the survival probability of less than 1-year was 18.9%, <3-year was 41.7% and <5-year was 61.2%. A subsequent calibration plot proved the prediction accuracy of the nomogram pattern. The closer of predicting cures are to the gray diagonal (actual curves), the more accurate the

nomogram pattern will be (Fig. 8B). The results of nomogram analysis demonstrated that the survival probability increased while the patient lived longer.

Discussion

The present study first evaluated the variation of cuproptosis-associated genes and found that CNV might affect the expression levels of cuproptosis-associated genes between normal tissues and COAD, indicating their potential role in tumorigenesis. Next, all patients were divided into two subtypes according to the following three criteria: Firstly, the area under the CDF curve is not increased obviously. When CDF reaches the approximate maximum value, the analysis result is reliable. Secondly, the inter-subtype correlation decreased, while




Figure 7. Immune function, checkpoints, TMB, MSI and drug susceptibility analysis. (A) The immune cell subpopulations related functions based on ssGSEA in high- and low-risk groups. * $P < 0.05$ and *** $P < 0.001$. (B) Immune checkpoints: Differences in the expression levels of immune checkpoints between the high- and low-risk groups. * $P < 0.05$, ** $P < 0.01$ and *** $P < 0.001$. (C) TMB in two risk score groups. (D) Spearman correlation analysis of the risk score and TMB. (E) Survival analysis between low and high TMB. (F) Relationships between risk score and MSI. (G-K) Relationships between risk score and immunotherapeutic sensitivity. TMB, tumor mutation burden; MSI, microsatellite instability; ssGSEA, single sample gene set enrichment analysis.

the intra-subtype correlation increased after clustering. Lastly, enough samples in the subtype were available. Compared to

subtype B, subtype A had improved survival and subtype B had more advanced-stage clinicopathological features.




Figure 8. Construction of a nomogram scoring pattern. (A) Nomogram scoring pattern for predicting the 1-, 3-, 5-year survival probability of single patients with COAD. (B) Calibration curves of the nomogram for predicting of 1-, 3-, 5-year observed OS in entire group. (C) Calibration curves of the nomogram for predicting of 1-, 3-, 5-year observed OS in training group. (D) Calibration curves of the nomogram for predicting of 1-, 3-, 5-year observed OS in testing group. COAD, colon adenocarcinoma; OS, overall survival.

KEGG and Hallmark enrichment analyses were applied and determined that subtype A was mainly enriched in molecular processes or tumor immune-related signaling pathways. In addition, three gene subtypes were identified on the base of prognosis-related DEGs. The subtype with higher expression of cuproptosis-associated genes showed an overall survival advantage over those with lower gene expression, indicating that these upregulated cuproptosis-associated genes may inhibit COAD by mediating pathways associated with cell death and immune responses.

Considering the heterogeneity of patients, the risk score was constructed based on seven key genes. As predicted, patients with the low-risk score had more prolonged overall survival compared with those with the high-risk score. However, patients with high-risk score displayed significant immune infiltration, immune function, immune checkpoints, TMB, MSI and drug susceptibility. The tumor cells surrounding TME include tumor immune infiltrating cells, fibroblasts, lymphocytes and inflammatory cells derived from bone marrow (32). The number of tumor-infiltrating T cells in colorectal cancer tissues were higher compared with that in normal tissues and the higher infiltration indicated an improved prognosis (33-35).

Activated CD4⁺ and CD8⁺ T cells play an important role in the immune defense of colorectal cancer (33,36). By contrast, Tregs suppress abnormal immune responses to self-antigens

as well as anticancer immune responses, which was associated with poor prognosis (37) and some studies have shown that immunosuppressive and tumor-associated macrophage M2 (38,39) or Tregs are associated with poor prognosis. As shown in Fig. S2, the high-risk group had higher fractions of macrophage M2 and Tregs. MSI-H is generally considered to predict a good prognosis of tumors, but there are exceptions. The high-risk group in the present study had a poor prognosis due to low tumor purity and the presence of immunosuppressive cells, such as M2 Macrophages and Tregs. Moreover, the high-risk group correlated with impaired antitumor immunity, including the immune function of T cell co inhibition and type I/II IFN response (Fig. 7A). Therefore, the weakened antitumor immunity in patients (40) in the high-risk group may be the reason for their poor prognosis (29,30). Research has shown the abundance of B cell enrichment involved in immune responses, which was identified as the most powerful prognostic factor for prolonged survival (41,42). In addition, tumor-infiltrating B cells are associated with an improved prognosis and a lower risk of recurrence in colorectal cancer (43,44). In the present study, the enrichment of plasma B cells in low-risk group was higher and this might be the reason the low-risk group had improved survival than the high-risk group.

The different distributions of 7 model genes in epithelial cells of normal tissue, HCT-116 and HT-29 cells were analyzed

by RT-qPCR. Most genes were expressed in colon tumor cells, indicating that these genes were involved in the colon tumor progression. *HSPB7* expression was the highest in HCT-116 and HT-29 cells, and it is mainly released by endothelial cells and plays a key role in regulating the balance of angiogenesis (45). It is closely associated with the depth of primary colorectal tumors (46). *PMM2* and *EPHB2* were observed at higher levels in COAD tissues (47,48). *KDM3A* is overexpressed in various types of cancer and this gene appears to be an ideal target for cancer therapy (49).

Based on the immune system of the patient, tumor immunotherapy can enhance the immune response against tumor escape and reduce the off-target effect. The immunotherapy includes immune checkpoint inhibitors (ICIs), thymosin and biological cells (such as dendritic cells and chimeric antigen receptor T cells). CTLA 4, PD-1 and PD-L1 have been widely used in clinical research and studies have proved their safety and effectiveness (50,51). ICIs have been used to treat colorectal cancer (52). The present study observed higher expression levels of checkpoints in the high-risk group indicating that the high-risk group would have improved drug susceptibility. Immunotherapy with the anti-PD-1 nivolumab displays favorable outcomes compared with conventional therapies (53). Elesclomol plays a potential role in the treatment of colorectal cancer (54). The patients with high-risk scores might be more sensitive to ICIs responses and Elesclomol, Indoximod, nivolumab and Pazopanib had a treatment advantage in the high-risk group. ICIs can effectively treat advanced MSI-H tumors and MSI-H can be used as a biomarker for treatment (55). The present study hypothesized that the proportion of patients with MSI-H was higher in the high-risk group. Consistent with the results, the expression levels of PD-1, PD-L1 and CTLA4 were significantly upregulated in MSI-H patients (56).

Finally, a quantitative nomogram predicting pattern was established by integrating risk score and clinical characteristics of COAD to further improve the prognosis and health assessment of the patient and improve the feasibility of the risk score. To provide suggestions for clinical treatment, this nomogram prediction pattern can be used to predict the survival probability of each patient at a specific time.

Acknowledgements

Not applicable.

Funding

The present study was supported by an academic research project of Jiangnan University (grant nos. 1010/08190006 and 1010/08190001).

Availability of data and materials

All data generated or analyzed during this study are included in this published article and its supplementary material.

Authors' contributions

GY and BS conceived and designed the study, and GY conducted the data analysis and wrote the manuscript. HW

carried out experimental verification. All the authors read and approved the final manuscript. GY and BS confirm the authenticity of all the raw data.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* 71: 209-249, 2021.
2. Almatroudi A: The incidence rate of colorectal cancer in Saudi Arabia: An observational descriptive epidemiological analysis. *Int J Gen Med* 13: 977-990, 2020.
3. Kanani A, Veen T and Søreide K: Neoadjuvant immunotherapy in primary and metastatic colorectal cancer. *Br J Surg* 108: 1417-1425, 2021.
4. Goc J, Lv M, Bessman NJ, Flamar AL, Sahota S, Suzuki H, Teng F, Putzel GG; JRI Live Cell Bank; Eberl G, *et al*: Dysregulation of ILC3s unleashes progression and immunotherapy resistance in colon cancer. *Cell* 184: 5015-5030.e16, 2021.
5. Jiang Y, Huo Z, Qi X, Zuo T and Wu Z: Copper-induced tumor cell death mechanisms and antitumor theragnostic applications of copper complexes. *Nanomedicine (Lond)* 17: 303-324, 2022.
6. Lelièvre P, Sancey L, Coll JL, Deniaud A and Busser B: The multifaceted roles of copper in cancer: A trace metal element with dysregulated metabolism, but also a target or a bullet for therapy. *Cancers (Basel)* 12: 3594, 2020.
7. da Silva DA, De Luca A, Squitti R, Rongioletti M, Rossi L, Machado CML and Cerchiaro G: Copper in tumors and the use of copper-based compounds in cancer treatment. *J Inorg Biochem* 226: 111634, 2022.
8. De Luca A, Barile A, Arciello M and Rossi L: Copper homeostasis as target of both consolidated and innovative strategies of anti-tumor therapy. *J Trace Elem Med Biol* 55: 204-213, 2019.
9. Tsvetkov P, Coy S, Petrova B, Dreishpoon M, Verma A, Abdusamad M, Rossen J, Joesch-Cohen L, Humeidi R, Spangler RD, *et al*: Copper induces cell death by targeting lipoylated TCA cycle proteins. *Science* 375: 1254-1261, 2022.
10. Yang S, He X, Zhao J, Wang D, Guo S, Gao T, Wang G, Jin C, Yan Z, Wang N, *et al*: Mitochondrial transcription factor A plays opposite roles in the initiation and progression of colitis-associated cancer. *Cancer Commun (Lond)* 41: 695-714, 2021.
11. Baszuk P, Marciniak W, Derkacz R, Jakubowska A, Cybulski C, Gronwald J, Dębniak T, Huzarski T, Białkowska K, Pietrzak S, *et al*: Blood copper levels and the occurrence of colorectal cancer in Poland. *Biomedicines* 9: 1628, 2021.
12. Lutsenko S: Dynamic and cell-specific transport networks for intracellular copper ions. *J Cell Sci* 134: jcs240523, 2021.
13. Baldari S, Di Rocco G, Heffern MC, Su TA, Chang CJ and Toietta G: Effects of copper chelation on BRAF^{V600E} positive colon carcinoma cells. *Cancers (Basel)* 11: 659, 2019.
14. Cui L, Gouw AM, LaGory EL, Guo S, Attarwala N, Tang Y, Qi J, Chen YS, Gao Z, Casey KM, *et al*: Mitochondrial copper depletion suppresses triple-negative breast cancer in mice. *Nat Biotechnol* 39: 357-367, 2021.
15. Davis CI, Gu X, Kiefer RM, Ralle M, Gade TP and Brady DC: Altered copper homeostasis underlies sensitivity of hepatocellular carcinoma to copper chelation. *Metallomics* 12: 1995-2008, 2020.
16. Zhao S, Ye Z and Stanton R: Misuse of RPKM or TPM normalization when comparing across samples and sequencing protocols. *RNA* 26: 903-909, 2020.

17. Conesa A, Madrigal P, Tarazona S, Gomez-Cabrero D, Cervera A, McPherson A, Szczesniak MW, Gaffney DJ, Elo LL, Zhang X and Mortazavi A: A survey of best practices for RNA-seq data analysis. *Genome Biol* 17: 13, 2016.
18. Gautier L, Cope L, Bolstad BM and Irizarry RA: affy-analysis of Affymetrix GeneChip data at the probe level. *Bioinformatics* 20: 307-315, 2004.
19. Song W, Ren J, Xiang R, Kong C and Fu T: Identification of pyroptosis-related subtypes, the development of a prognosis model, and characterization of tumor microenvironment infiltration in colorectal cancer. *Oncoimmunology* 10: 1987636, 2021.
20. Sturm G, Finotello F, Petitprez F, Zhang JD, Baumbach J, Fridman WH, List M and Anechik T: Comprehensive evaluation of transcriptome-based cell-type quantification methods for immuno-oncology. *Bioinformatics* 35: i436-i445, 2019.
21. Sui Z, Wu X, Du L, Wang H, Yuan L, Zhang JV and Yu Z: Characterization of the immune cell infiltration landscape in esophageal squamous cell carcinoma. *Front Oncol* 12: 879326, 2022.
22. Iasonos A, Schrag D, Raj GV and Panageas KS: How to build and interpret a nomogram for cancer prognosis. *J Clin Oncol* 26: 1364-1370, 2008.
23. Sebestyén E, Singh B, Miñana B, Pagès A, Mateo F, Pujana MA, Valcárcel J and Eyra E: Large-scale analysis of genome and transcriptome alterations in multiple tumors unveils novel cancer-relevant splicing networks. *Genome Res* 26: 732-744, 2016.
24. Koch A, Joosten SC, Feng Z, de Ruijter TC, Draht MX, Melotte V, Smits KM, Veeck J, Herman JG, Van Neste L, *et al*: Analysis of DNA methylation in cancer: Location revisited. *Nat Rev Clin Oncol* 15: 459-466, 2018.
25. Lambert SA, Jolma A, Campitelli LF, Das PK, Yin Y, Albu M, Chen X, Taipale J, Hughes TR and Weirauch MT: The human transcription factors. *Cell* 172: 650-665, 2018.
26. Xu J, Dai S, Yuan Y, Xiao Q and Ding K: A prognostic model for colon cancer patients based on eight signature autophagy genes. *Front Cell Dev Biol* 8: 602174, 2020.
27. Kang N, Xie X, Zhou X, Wang Y, Chen S, Qi R, Liu T and Jiang H: Identification and validation of EMT-immune-related prognostic biomarkers CDKN2A, CMTM8 and ILK in colon cancer. *BMC Gastroenterol* 22: 190, 2022.
28. Lv H, Liu X, Zeng X, Liu Y, Zhang C, Zhang Q and Xu J: Comprehensive analysis of cuproptosis-related genes in immune infiltration and prognosis in Melanoma. *Front Pharmacol* 13: 930041, 2022.
29. Zhang C, Cheng W, Ren X, Wang Z, Liu X, Li G, Han S, Jiang T and Wu A: Tumor purity as an underlying key factor in glioma. *Clin Cancer Res* 23: 6279-6291, 2017.
30. Mao Y, Feng Q, Zheng P, Yang L, Liu T, Xu Y, Zhu D, Chang W, Ji M, Ren L, *et al*: Low tumor purity is associated with poor prognosis, heavy mutation burden, and intense immune phenotype in colon cancer. *Cancer Manag Res* 10: 3569-3577, 2018.
31. Havel JJ, Chowell D and Chan TA: The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. *Nat Rev Cancer* 19: 133-150, 2019.
32. Turley SJ, Cremasco V and Astarita JL: Immunological hallmarks of stromal cells in the tumour microenvironment. *Nat Rev Immunol* 15: 669-682, 2015.
33. Ma R, Yuan D, Guo Y, Yan R and Li K: Immune effects of $\gamma\delta$ T cells in colorectal cancer: A review. *Front Immunol* 11: 1600, 2020.
34. Kuwahara T, Hazama S, Suzuki N, Yoshida S, Tomochika S, Nakagami Y, Matsui H, Shindo Y, Kanekiyo S, Tokumitsu Y, *et al*: Intratumoural-infiltrating CD4+ and FOXP3+ T cells as strong positive predictive markers for the prognosis of resectable colorectal cancer. *Br J Cancer* 121: 659-665, 2019.
35. Governa V, Trella E, Mele V, Tornillo L, Amicarella F, Cremonesi E, Muraro MG, Xu H, Droeser R, Däster SR, *et al*: The Interplay between neutrophils and CD8+ T cells improves survival in human colorectal cancer. *Clin Cancer Res* 23: 3847-3858, 2017.
36. Zhang L, Yu X, Zheng L, Zhang Y, Li Y, Fang Q, Gao R, Kang B, Zhang Q, Huang JY, *et al*: Lineage tracking reveals dynamic relationships of T cells in colorectal cancer. *Nature* 564: 268-272, 2018.
37. Tanaka A and Sakaguchi S: Regulatory T cells in cancer immunotherapy. *Cell Res* 27: 109-118, 2017.
38. Pan Y, Yu Y, Wang X and Zhang T: Tumor-associated macrophages in tumor immunity. *Front Immunol* 11: 583084, 2020.
39. Sousa S, Brion R, Lintunen M, Kronqvist P, Sandholm J, Mönkkönen J, Kellokumpu-Lehtinen PL, Laitinen S, Tynniinen O, Joensuu H, *et al*: Human breast cancer cells educate macrophages toward the M2 activation status. *Breast Cancer Res* 17: 101, 2015.
40. Liang JY, Wang DS, Lin HC, Chen XX, Yang H, Zheng Y and Li YH: A novel ferroptosis-related gene signature for overall survival prediction in patients with hepatocellular carcinoma. *Int J Biol Sci* 16: 2430-2441, 2020.
41. Helmink BA, Reddy SM, Gao J, Zhang S, Basar R, Thakur R, Calderaro J, Jeng YM, Hsiao LP, Lacroix L, Bougouin A, *et al*: B cells and tertiary lymphoid structures promote immunotherapy response. *Nature* 577: 549-555, 2020.
42. Petitprez F, de Reyniès A, Keung EZ, Chen TW, Sun CM, Calderaro J, Jeng YM, Hsiao LP, Lacroix L, Bougouin A, *et al*: B cells are associated with survival and immunotherapy response in sarcoma. *Nature* 577: 556-560, 2020.
43. Berntsson J, Nodin B, Eberhard J, Micke P and Jirstrom K: Prognostic impact of tumour-infiltrating B cells and plasma cells in colorectal cancer. *Int J Cancer* 139: 1129-1139, 2016.
44. Meshcheryakova A, Tamandl D, Bajna E, Stift J, Mittlboeck M, Svoboda M, Heiden D, Stremtizer S, Jensen-Jarolim E, Grünberger T, *et al*: B cells and ectopic follicular structures: Novel players in anti-tumor programming with prognostic power for patients with metastatic colorectal cancer. *PLoS One* 9: e99008, 2014.
45. Lee YJ, Lee HJ, Choi SH, Jin YB, An HJ, Kang JH, Yoon SS and Lee YS: Soluble HSPB1 regulates VEGF-mediated angiogenesis through their direct interaction. *Angiogenesis* 15: 229-242, 2012.
46. Hung CS, Huang CY, Hsu YW, Makondi PT, Chang WC, Chang YJ, Wang JY and Wei PL: HSPB1 rs2070804 polymorphism is associated with the depth of primary tumor. *J Cell Biochem* 121: 63-69, 2020.
47. Cui Z, Sun G, Bhandari R, Lu J, Zhang M, Bhandari R, Sun F, Liu Z and Zhao S: Comprehensive analysis of glycolysis-related genes for prognosis, immune features, and candidate drug development in colon cancer. *Front Cell Dev Biol* 9: 684322, 2021.
48. Herath NI, Spanevello MD, Doecke JD, Smith FM, Poupponnnot C and Boyd AW: Complex expression patterns of Eph receptor tyrosine kinases and their ephrin ligands in colorectal carcinogenesis. *Eur J Cancer* 48: 753-762, 2012.
49. Cho HS, Toyokawa G, Daigo Y, Hayami S, Masuda K, Ikawa N, Yamane Y, Maejima K, Tsunoda T, Field HI, *et al*: The JmJC domain-containing histone demethylase KDM3A is a positive regulator of the G1/S transition in cancer cells via transcriptional regulation of the HOXA1 gene. *Int J Cancer* 131: E179-E189, 2012.
50. Wang Y, Zhang H, Liu C, Wang Z, Wu W, Zhang N, Zhang L, Hu J, Luo P, Zhang J, *et al*: Immune checkpoint modulators in cancer immunotherapy: Recent advances and emerging concepts. *J Hematol Oncol* 15: 111, 2022.
51. Bagchi S, Yuan R and Engleman EG: Immune checkpoint inhibitors for the treatment of cancer: Clinical impact and mechanisms of response and resistance. *Annu Rev Pathol* 16: 223-249, 2021.
52. Marin-Acevedo JA, Dholaria B, Soyano AE, Knutson KL, Chumsri S and Lou Y: Next generation of immune checkpoint therapy in cancer: New developments and challenges. *J Hematol Oncol* 11: 39, 2018.
53. Roudko V, Cimen Bozkus C, Greenbaum B, Lucas A, Samstein R and Bhardwaj N: Lynch syndrome and MSI-H cancers: From mechanisms to 'off-the-shelf' cancer vaccines. *Front Immunol* 12: 757804, 2021.
54. Llosa NJ, Cruise M, Tam A, Wicks EC, Hechenbleikner EM, Taube JM, Blosser RL, Fan H, Wang H, Luber BS, *et al*: The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. *Cancer Discov* 5: 43-51, 2015.
55. Ieranò C, Righelli D, D'Alterio C, Napolitano M, Portella L, Rea G, Auletta F, Santagata S, Trotta AM, Guardascione G, *et al*: In PD-1+ human colon cancer cells NIVOLUMAB promotes survival and could protect tumor cells from conventional therapies. *J Immunother Cancer* 10: e004032, 2022.
56. Gao W, Huang Z, Duan J, Nice EC, Lin J and Huang C: Elesclomol induces copper-dependent ferroptosis in colorectal cancer cells via degradation of ATP7A. *Mol Oncol* 15: 3527-3544, 2021.



This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.